Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban in Human Breast Milk
NCT06831474Phase 1Recruiting
- Sponsor
- Thomas Jefferson University
- Start
- Jul 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rivaroxaban in venous thromboembolism (VTE) (2 arms), sponsored by Thomas Jefferson University. Primary endpoints: Concentration of rivaroxaban in breast milk at 1 day, Absolute infant dose of rivaroxaban at 6 weeks and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06831474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06831474.